Shares of ArriVent BioPharma rose after the company announced positive initial data from a Phase 1 trial of treatment for gastrointestinal cancers. The stock gained 9.3% to $22.95 in premarket trading ...

Incyte (Nasdaq:INCY) announced new results from its advancing oncology portfolio, including updated results for its KRAS G12D ...

Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and ...

Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms ...

Dak Lak Province in Vietnam’s Central Highlands has recorded four cases of Whitmore's disease, including one death, since the ...

AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin has doubled overall survival in a late-stage trial for ...

AstraZeneca's groundbreaking cancer drug significantly boosts stomach cancer survival rates, offering hope to patients.

Global Fabry Disease Market size is expected to be worth around US$ 5.3 Billion by 2034 from US$ 2.5 Billion in 2024.

GLP-1 receptor agonists support weight loss and metabolic control in people with inflammatory bowel disease, while ...

A breakthrough treatment has made significant progress, showing promising results in decreasing recurrence and death from a ...

New treatments are in development for inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. Find out what ...

Using ultrasound images to monitor inflammatory bowel disease is catching on in the United States. Find out what it is, how ...